Several groundbreaking treatments are reshaping glucose care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as leading options. Retatrutide, a double GIP and GLP-1 target activator, demonstrates substantial weight loss along with better blood sugar control. Cagrillintide, another GLP-1 stimulant, is currently in clinical as